- CYT-108 is a recombinant protease inhibitor therapy with potential disease-modifying effects - JUPITER, Fla., April 1, 2025 /PRNewswire/ -- Cytonics, an early-stage biopharmaceutical company ...

has granted clinical trial authorization (CTA) for Vasa to commence a Phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and pharmacokinetics of its investigational drug ...

First-in-human VIDAR-1 trial begins with the deployment ... announces the authorisation of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under ...

Human clinical trials are the final stage ... from people who agree to be part of the studies. Joining a clinical trial has rewards, but there are also possible drawbacks for participants.

Vivani Medical began the LIBERATE-1 trial, testing a six-month exenatide implant for chronic weight management in Australia. The study uses NanoPortal technology, with results expected in mid-2025 ...